Madrigal Pharmaceuticals’ (MDGL) stocks experienced a significant surge of 12.78% during the pre-market session on Tuesday 5th August 2025, resulting in a price of $352.00 compared to the previous closing at $312.11.
This dramatic increase was largely due to the company’s Q2 2025 earnings report, which was released before the market opened. Madrigal Pharmaceuticals reported a loss of $1.9 per share, significantly better than the anticipated loss of $3.74 and a 73% decrease from the same period last year.
Furthermore, the company reported a revenue of $212.8 million, significantly exceeding analysts’ estimates of $158.9 million and showing an increase over the same quarter last year.
